Clinical trials: Transplant Patients
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant…
- Conditions
- Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
- Trial name
- NCT02652130
- Testing
- Remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- Mesoblast, Inc.
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Burns
Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in…
- Trial name
- NCT06745557
- Testing
- denovoSkin(TM), STSG
- Where
- 19 sites in Belgium, France and 7 more
- Volunteers
- 70 people
- Sponsor
- CUTISS AG
Bronchiolitis Obliterans, Obliterative Bronchiolitis
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
- Conditions
- Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome
- Trial name
- BOSTON-3 (NCT04039347)
- Testing
- Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg
- Where
- 37 sites in United States, Austria and 7 more
- Volunteers
- 164 people
- Sponsor
- Zambon SpA
Burn Injury, Skin Graft
A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
Part A The primary objective of Part A will be to verify performance and safety of Mepitel® Ag, a meshed, non- adherent soft silicone wound contact layer containing silver in the treatment of skin grafts in surgical burn…
- Trial name
- MpTAg03 (NCT02210208)
- Testing
- Mepitel® Ag, Mepilex® Transfer Ag
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Molnlycke Health Care AB
Sickle Cell Disease
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle…
- Trial name
- NCT04443907
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Failure and Rejection
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome…
- Trial name
- NCT03611621
- Testing
- Imlifidase
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 31 people
- Sponsor
- Hansa Biopharma AB
Steroid Refractory GVHD
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute…
- Trial name
- AURORA (NCT06343792)
- Testing
- RLS-0071
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- ReAlta Life Sciences, Inc.
Kidney Transplantation
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.
- Trial name
- NCT00403416
- Testing
- AEB071, Mycophenolic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 215 people
- Sponsor
- Novartis Pharmaceuticals
Poor Graft Function
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks…
- Trial name
- ELTION (NCT03718533)
- Testing
- Eltrombopag
- Where
- 7 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
BKV Infection, EBV Infection
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after…
- Conditions
- BKV Infection, EBV Infection, CMV Infection
- Trial name
- NCT07670468
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- LucasBio
Fractures, Bone
Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma
This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes.
- Trial name
- ARTIST (NCT06256458)
- Testing
- NanoBone® Bone Graft
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Artoss Inc.
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Glomerulonephritis
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence…
- Trial name
- NCT03832114
- Testing
- LNP023
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Rejection
Transition of Renal Patients Using AlloSure Into Community Kidney Care
Patients undergoing kidney transplantation alone (either de-novo or re-transplant) at a participating hospital are routinely surveyed with interval blood tests as part of standard post-operative care through outpatient…
- Trial name
- TRACK (NCT04601155)
- Testing
- AlloSure
- Where
- 18 sites in United States
- Volunteers
- 248 people
- Sponsor
- CareDx
Multiple Myeloma
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF…
- Trial name
- NCT06514508
- Testing
- Motixafortide+G-CSF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.
- Trial name
- NCT01380535
- Testing
- ECP Methoxsalen, Standard of Care
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
Acute Peripheral Arterial Occlusion
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion.
- Trial name
- NCT01222117
- Testing
- Plasmin, Plasminogen Activator
- Where
- 39 sites in United States, Belgium and 10 more
- Volunteers
- 174 people
- Sponsor
- Grifols Therapeutics LLC
Leukemia
A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT).
- Trial name
- NCT00756912
- Testing
- E5564
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.